Pradaxa ® (dabigatran etexilate) is a prescription medication manufactured by Boehringer Ingelheim. It is a blood thinning medication used for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation). In November 2011, Boehringer Ingelheim confirmed reports of 260 people worldwide suffering a fatal bleed while taking Pradaxa. In December 2011, the FDA issued a safety announcement that it is evaluating post-marketing reports of serious bleeding events in patients taking Pradaxa.
If taking Pradaxa® Resulted in Internal Bleeding, Hemorrhage, or Death you May be Entitled to Compensation.
Pradaxa injury cases are now part of a multi-district litigation being heard in Federal Court in Illinois by Judge Herman. Judge Herman is the same judge who is presiding over the YAZ pharmaceutical cases.
Judge Herman has recently ordered that the first Pradaxa trial begin by 2014. He has ordered that claims can be directly filed against both American and Foreign manufactures. This means that service of process can be affected by mail. This eliminates the requirement that claimants serve defendants with formal Service of Process. Additional orders are now in place as to how depositions and other discovery is conducted. This will simplify the discovery process.
Our Pradaxa accident law firm is not investigating claims for those who have been harmed by taking this medication.
Pradaxa law suits are now filed in Federal Court in Illinois no matter where the claimant resides as part of a MDL (Multi District Litigation.) The Hon. David R. Herndon who is the United States District Court Chief Judge for the Southern District of Illinois has been assigned to the case. This is the same Judge that is presiding over the YAZ class action.
So far, hundreds of injured Pradaxa patients have filed lawsuits alleging that the blood thinner caused uncontrollable bleeding, serious injuries, and death. Our lawyers will sue for people who have been harmed by Pradaxa and help them obtain fair and reasonable compensation.
According the FDA, over 1 million Pradaxa prescriptions have been filled since the drug was approved in October 2010. Pradaxa or Dabigatran Etexilate is given to reduce the risk for strokes and blood clots. It is widely prescribed as an alternative to Coumadin. The main difference is that Coumadin can be reversed after an emergency bleed, while Pradaxa has no known reversal agent.
Judge Herndon has ordered that the first trials commence by 2014. He has ordered that claimants can file directly into the MDL to avoid the expense of filing and serving individual lawsuits around the country. In addition, service of process against both domestic and foreign manufactures can be satisfied by mail.
On December 19, 2012 the FDA issued another safety alert warning that patients with artificial heart valves should not take Pradaxa. A clinical study in Europe had to be cut short because of an increase risk for strokes, heart attacks and bleeding incidents. Pradaxa continues to prove to be more dangerous than Warafin.
You can find more information on Pradaxa claims on our blog post Why Pradaxa Is Dangerous.